Güldal Esendağlı

Efficacy of a novel LyP-1-containing self-microemulsifying drug delivery system (SMEDDS) for active targeting to breast cancer

Selin Seda Timur, Diğdem Yöyen-Ermiş, Güldal Esendağlı et al. · European Journal of Pharmaceutics and Biopharmaceutics · 2019 · 39 citations

Pharmacy, Pharmaceutics, Pharmacology +14

Tumor-Infiltrating Lymphocytes (TIL), Tertiary Lymphoid Structures (TLS), and Expression of PD-1, TIM-3, LAG-3 on TIL in Invasive and In Situ Ductal Breast Carcinomas and Their Relationship with Prognostic Factors

Elif Acar, Güldal Esendağlı, Ozan Yazıcı et al. · Clinical Breast Cancer · 2022 · 25 citations

Medicine, Immunology, Oncology +17

Cucurbitacin B and cisplatin induce the cell death pathways in MB49 mouse bladder cancer model

Yener Kurman, Asiye Uğraş Dikmen, Güldal Esendağlı et al. · Experimental Biology and Medicine · 2020 · 21 citations · Full text

Medicine, Oncology, Pharmacology +17

The importance of serum biglycan levels as a fibrosis marker in patients with chronic hepatitis B

Rafiye Çiftçiler, Seren Özeni̇rler, Ayşegül Atak Yücel et al. · Journal of Clinical Laboratory Analysis · 2016 · 19 citations · Full text

Medicine, Pathology, Diagnostic Pathology +16

Effects of thiostrepton alone or in combination with selumetinib on triple-negative breast cancer metastasis

Funda Demırtaş Korkmaz, İrem Doğan, Güldal Esendağlı et al. · Molecular Biology Reports · 2022 · 12 citations

Medicine, Oncology, Pharmacology +12